[go: up one dir, main page]

AR044613A1 - Heteroaril derivados de sulfonamidas como moduladores del receptor de quimioquina (ccr4) - Google Patents

Heteroaril derivados de sulfonamidas como moduladores del receptor de quimioquina (ccr4)

Info

Publication number
AR044613A1
AR044613A1 ARP040101942A ARP040101942A AR044613A1 AR 044613 A1 AR044613 A1 AR 044613A1 AR P040101942 A ARP040101942 A AR P040101942A AR P040101942 A ARP040101942 A AR P040101942A AR 044613 A1 AR044613 A1 AR 044613A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
group
chemioquine
sulfonamids
Prior art date
Application number
ARP040101942A
Other languages
English (en)
Inventor
David Cheshire
Nicholas Kindon
Michael Stocks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR044613A1 publication Critical patent/AR044613A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Procesos de preparación y composiciones farmacéuticas que los comprenden. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1) y sale o solvatos aceptables para uso farmacéutico, en el cual: Ar1 es diclorofenilo o tienilo sustituido por uno o dos átomos de cloro; A es una pirimidina, pirazidina o un anillo 1,2,4-triazina, cada uno de los cuales se puede sustituir opcionalmente por uno o más grupos seleccionados entre hidroxilo, halógeno, ciano, C1-6 alquilo, C1-6 alcoxi o C3-6 cicloalquilo donde en cada caso el grupo alquilo se puede sustituir con 1-3 átomos de flúor, un grupo ciano o un grupo hidroxi; R1 es C1-6 alquilo o C3-6 cicloalquilo cada uno de los cuales se puede sustituir opcionalmente con 1-3 átomos de flúor o un grupo ciano o R1 es C3-6 alquenilo o C3-6 alquinilo o (C1-6)alquil-R2; R2 es un grupo arilo o un anillo heteroaromático de 5-7 miembros que contiene 1-4 heteroátomos seleccionados entre nitrógeno, oxígeno o azufre cada uno de los cuales se puede sustituir opcionalmente por 1-3 grupos seleccionados entre halógeno, C1-6 alquilo, C1-6 alcoxi, =O, =S, CN o (CH2)nOH donde n es 1 ó 2.
ARP040101942A 2003-06-05 2004-06-04 Heteroaril derivados de sulfonamidas como moduladores del receptor de quimioquina (ccr4) AR044613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301654A SE0301654D0 (sv) 2003-06-05 2003-06-05 Novel compounds

Publications (1)

Publication Number Publication Date
AR044613A1 true AR044613A1 (es) 2005-09-21

Family

ID=29212393

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101942A AR044613A1 (es) 2003-06-05 2004-06-04 Heteroaril derivados de sulfonamidas como moduladores del receptor de quimioquina (ccr4)

Country Status (9)

Country Link
US (1) US20060189613A1 (es)
EP (1) EP1633723A1 (es)
JP (1) JP2006526619A (es)
AR (1) AR044613A1 (es)
SA (1) SA04250149A (es)
SE (1) SE0301654D0 (es)
TW (1) TW200509935A (es)
UY (1) UY28345A1 (es)
WO (1) WO2004108690A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328007B (en) * 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) * 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
WO2007063935A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 芳香族化合物
TW200730512A (en) * 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
CN105377837B (zh) 2013-05-14 2017-08-04 活跃生物技术有限公司 用作s100‑抑制剂的n‑(杂芳基)磺酰胺衍生物
TW201811766A (zh) * 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
KR20200104291A (ko) * 2017-11-06 2020-09-03 랩트 테라퓨틱스, 인크. 항암제
KR102912146B1 (ko) 2018-12-06 2026-01-14 다이이찌 산쿄 가부시키가이샤 시클로알칸-1,3-디아민 유도체
JP2022519301A (ja) * 2019-02-06 2022-03-22 ノバルティス アーゲー Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体及び疾患の処置におけるそれらの使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
JP2004509874A (ja) * 2000-09-25 2004-04-02 アクテリオン　ファマシューティカルズ　リミテッド 新規なアリールアルカン−スルフォンアミド類
WO2002030357A2 (en) * 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
US20060004010A1 (en) * 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
SE0301650D0 (sv) * 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
WO2004108690A1 (en) 2004-12-16
SA04250149A (ar) 2005-12-03
US20060189613A1 (en) 2006-08-24
EP1633723A1 (en) 2006-03-15
SE0301654D0 (sv) 2003-06-05
UY28345A1 (es) 2005-01-31
JP2006526619A (ja) 2006-11-24
TW200509935A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR082826A2 (es) Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
NI201000011A (es) Derivados de pirimidina 934.
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
AR075975A1 (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
ECSP045073A (es) Nuevos derivados de piperazina
AR044613A1 (es) Heteroaril derivados de sulfonamidas como moduladores del receptor de quimioquina (ccr4)
AR043487A1 (es) Heterociclos fusionados de pirimidina y usos de los mismos
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
AR059032A1 (es) Combinacion de derivados de triazina y sensibilizadores de insulina
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
PE20070438A1 (es) Derivados de 4-fenil-pirimidina-6-sustituida-2-carbonitrilo como inhibidores de catepsina k y catepsina s
AR061265A1 (es) Piperidinas 2,5- disustituidas
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
AR052370A1 (es) Tiazolidinonas y su uso como inhibidores de la poloquinasa(plk)
AR078770A1 (es) Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure